📊 PBSV Key Takeaways
Is Pharma-Bio Serv, Inc. (PBSV) a Good Investment?
Pharma-Bio Serv exhibits fundamental operational distress with negative operating margins (-4.1%) and declining revenue (-5.3% YoY), indicating the core business is unprofitable. The most critical issue is the severe disconnect between positive accounting earnings and negative operating cash flow (-$390.1K), suggesting the reported net income is not backed by sustainable cash generation. While the balance sheet provides temporary protection with minimal debt and strong liquidity, the company is burning cash operationally and returning minimal capital to shareholders (ROE 0.3%), requiring urgent operational restructuring.
Why Buy Pharma-Bio Serv, Inc. Stock? PBSV Key Strengths
- Minimal leverage with zero long-term debt and low debt-to-equity ratio
- Strong liquidity position with current ratio of 4.03x and $5.8M cash reserves
- Positive net income of $32.9K showing some accounting profitability
PBSV Stock Risks: Pharma-Bio Serv, Inc. Investment Risks
- Negative operating margins (-4.1%) indicate core business operations are unprofitable
- Severe cash flow deterioration: negative operating cash flow of -$390.1K despite positive net income signals low-quality earnings and unsustainable profitability
- Declining revenue trend (-5.3% YoY) combined with inability to control costs suggests structural business challenges
- Extremely poor capital efficiency with ROE of 0.3% and ROA of 0.2% indicating minimal shareholder value creation
- Micro-cap OTC trading with limited liquidity and market depth
Key Metrics to Watch
- Operating cash flow trend - critical indicator of whether positive net income is sustainable
- Gross margin stability - monitor if margin compression will worsen profitability
- Cash burn rate and runway - at current -$392.6K FCF, cash reserves deplete in ~14.7 years unless operations improve
- Revenue stabilization - must return to growth to demonstrate business viability
Pharma-Bio Serv, Inc. (PBSV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.03x current ratio provides a solid financial cushion.
PBSV Profit Margin, ROE & Profitability Analysis
PBSV vs Services Sector: How Pharma-Bio Serv, Inc. Compares
How Pharma-Bio Serv, Inc. compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Pharma-Bio Serv, Inc. Stock Overvalued? PBSV Valuation Analysis 2026
Based on fundamental analysis, Pharma-Bio Serv, Inc. has mixed fundamental signals relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Pharma-Bio Serv, Inc. Balance Sheet: PBSV Debt, Cash & Liquidity
PBSV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Pharma-Bio Serv, Inc.'s revenue has declined by 56% over the 5-year period, indicating business contraction. The most recent EPS of $-0.03 indicates the company is currently unprofitable.
PBSV Revenue Growth, EPS Growth & YoY Performance
PBSV Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.3M | $8.5K | $0.00 |
| Q3 2025 | $2.0M | -$100.4K | $0.00 |
| Q2 2025 | $2.4M | $95.4K | $0.00 |
| Q1 2025 | $2.4M | $8.5K | $0.00 |
| Q3 2024 | $2.4M | -$309.2K | N/A |
| Q2 2024 | $2.4M | -$213.8K | N/A |
| Q1 2024 | $2.4M | -$270.7K | N/A |
| Q3 2023 | $4.6M | $288.0K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Pharma-Bio Serv, Inc. Dividends, Buybacks & Capital Allocation
PBSV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Pharma-Bio Serv, Inc. (CIK: 0001304161)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PBSV
What is the AI rating for PBSV?
Pharma-Bio Serv, Inc. (PBSV) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PBSV's key strengths?
Claude: Minimal leverage with zero long-term debt and low debt-to-equity ratio. Strong liquidity position with current ratio of 4.03x and $5.8M cash reserves.
What are the risks of investing in PBSV?
Claude: Negative operating margins (-4.1%) indicate core business operations are unprofitable. Severe cash flow deterioration: negative operating cash flow of -$390.1K despite positive net income signals low-quality earnings and unsustainable profitability.
What is PBSV's revenue and growth?
Pharma-Bio Serv, Inc. reported revenue of $2.3M.
Does PBSV pay dividends?
Pharma-Bio Serv, Inc. pays dividends, with $1.7M distributed to shareholders in the trailing twelve months.
Where can I find PBSV SEC filings?
Official SEC filings for Pharma-Bio Serv, Inc. (CIK: 0001304161) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PBSV's EPS?
Pharma-Bio Serv, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PBSV a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Pharma-Bio Serv, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PBSV stock overvalued or undervalued?
Valuation metrics for PBSV: ROE of 0.3% (sector avg: 16%), net margin of 1.4% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy PBSV stock in 2026?
Our dual AI analysis gives Pharma-Bio Serv, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PBSV's free cash flow?
Pharma-Bio Serv, Inc.'s operating cash flow is $-390.1K, with capital expenditures of $2.4K. FCF margin is -17.1%.
How does PBSV compare to other Services stocks?
Vs Services sector averages: Net margin 1.4% (avg: 10%), ROE 0.3% (avg: 16%), current ratio 4.03 (avg: 1.5).